Brief: Compass Therapeutics Announces Us FDA Clearance Of Application For A Phase 2 Study Of Ctx-009, A Bispecific Antibody
20/01/2022 13:39
Jan 20 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES US FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR A PHASE 2 STUDY OF
CTX-009, A BISPECIFIC ANTIBODY THAT SIMULTANEOUSLY TARGETS
DELTA-LIKE LIGAND 4 (DLL4) AND VASCULAR ENDOTHELIAL GROWTH
FACTOR A (VEGF-A)
Source text for Eikon: ID:nGNXcb50fm
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback